Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.53 |
| ▸ | MC4R | P32245 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6861732 | 1.00 | HTR2C (0.62) | HTR2CKCNH2MC4RP2RX7HDAC6 | |
| SCHEMBL21540803 | 0.88 | MC4R (0.50) | HTR2CMC4RALDH1A1 | |
| SCHEMBL26154086 | 0.85 | ALDH1A1 (0.65) | KCNH2MC4RP2RX7HDAC6ALDH1A1 | |
| SCHEMBL4035356 | 0.84 | ALDH1A1 (0.64) | HTR2CKCNH2MC4RP2RX7HDAC6 | |
| SCHEMBL20811287 | 0.84 | CHRM3 (0.49) | HTR2CKCNH2MC4RP2RX7ALDH1A1 | |
| SCHEMBL20790410 | 0.84 | CHRM3 (0.49) | HTR2CKCNH2MC4RP2RX7ALDH1A1 | |
| SCHEMBL20790409 | 0.84 | CHRM3 (0.49) | HTR2CKCNH2MC4RP2RX7ALDH1A1 | |
| SCHEMBL5534711 | 0.84 | HDAC6 (0.66) | KCNH2P2RX7HDAC6ALDH1A1USP2 | |
| Hydrochloric Acid SCHEMBL20790549 | 0.83 | CHRM3 (0.48) | HTR2CKCNH2MC4RP2RX7ALDH1A1 | |
| Hydrochloric Acid SCHEMBL20790547 | 0.83 | CHRM3 (0.48) | HTR2CKCNH2MC4RP2RX7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654834-B2 | Non-systemic TGR5 agonists | Venenum Biodesign, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190330191-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | Venenum Biodesign, LLC (US) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330191-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | GPR119, FFAR1, FFAR3 | HTR2C 722/4885KCNH2 1673/4885MC4R 82/4885 |
| US-10654834-B2 | Non-systemic TGR5 agonists | GPR119, SSTR5, FFAR3 | HTR2C 691/4885KCNH2 1546/4885MC4R 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.